Bashiru Ibrahim | Cancer Cells | Best Researcher Award

Published on by Oncology

Dr. Bashiru Ibrahim | Cancer Cells | Best Researcher Award

Research Fellow | University of Birmingham | United Kingdom

Dr. Bashiru Ibrahim is a highly skilled nanotoxicology and environmental science researcher with a strong academic foundation and extensive laboratory, teaching, and project management experience. He holds a PhD in Nanotoxicology from the University of Birmingham, where his research focused on the toxicological effects of metallic nanomaterials on lung epithelial cells, examining their interactions with cellular stress pathways, protein degradation systems, and intracellular uptake mechanisms. His academic journey also includes an MSc in Environmental Science with Distinction from the Islamic University in Uganda, where he studied the relationship between waterborne diseases and community water-handling practices, and a BSc in Biochemistry from Usmanu Danfodiyo University in Nigeria. Ibrahim has developed advanced expertise in nanomaterial synthesis, characterisation, cytotoxicity assays, flow cytometry, ICP-MS, confocal microscopy, and data analysis using multiple statistical software tools. He has worked as a Research Associate at the University of Birmingham, contributing to major international projects such as ACCORDs and NanoSolveIT, where he synthesised and characterised diverse nanomaterials, performed toxicological assessments using various cell lines and zebrafish models, and supported sustainable material design initiatives.

Citation Metrics (Google Scholar)

260

240

200

160

120

80

40

 

Citations
222
i10 Index
8
h-Index
9
        🟦 Citations          🟥I- 10 Index      🟩 h-index

View Google Scholar Profile

Featured Publications

Harini Keerthana SureshKumar | Cancer Cells | Best Researcher Award

Published on by Oncology

Ms. Harini Keerthana SureshKumar | Cancer Cells | Best Researcher Award 

PhD | Universitätsklinikum Heidelberg | Germany

Ms. Harini Keerthana SureshKumar is a dedicated biomedical scientist and emerging oncology researcher whose strong academic foundation and diverse research experience make her highly suitable for a Best Researcher Award. Currently pursuing her PhD in Anaesthesiology at Universitätsklinikum Heidelberg, she focuses on intraoperative cell salvage in oncological surgery while building on a solid background in molecular medicine and biomedical sciences. Her research journey includes extensive work in cell signaling, infection biology, microbial genomics, and cancer-related translational studies, supported by hands-on expertise in advanced laboratory techniques such as flow cytometry, immunoblotting, plasmid transfection, siRNA methodologies, viral assays, histology, microscopy, microbial culturing, genome analysis, and molecular diagnostics. She has contributed to impactful scientific literature, publishing in reputed journals including the European Journal of Surgical Oncology, Cell Communication and Signaling, Annals of Microbiology, Cells, and the Journal of Microbiology, Biotechnology and Food Sciences, along with depositing microbial genome sequences in the NCBI database. Ms. Harini has demonstrated research excellence through multiple roles as a research assistant and intern across prestigious German and Indian institutions, consistently applying complex methodologies to clinically relevant projects. Her academic achievements are complemented by recognition such as the Highly Recommended Poster Award at NATA’s 25th Anniversary Congress and winning the MIT COVID-19 Challenge in India. She has further strengthened her research competencies by completing specialized courses in microscopy, transgenic models, molecular intensive care, scientific ethics, and animal research regulations. Actively engaged in international conferences and scientific workshops, she reflects a strong commitment to innovation, collaboration, and scientific advancement. Alongside her technical abilities, she brings organizational strengths, problem-solving skills, and strong interpersonal capabilities, making her a promising young scientist with clear potential for significant future contributions to oncology and biomedical research.

Profile: ORCID

Featured Publications

  1. SureshKumar, H., Schenz, J., Waters, J. H., Weigand, M. A., Seyfried, T., Juratli, M. A., Frietsch, T., & Fischer, D. (2025). Revisiting the safety of intraoperative cell salvage in cancer surgery: How to evaluate the functional properties of remaining cancer cells. European Journal of Surgical Oncology. DOI: 10.1016/j.ejso.2025.110532

  2. Hornung, F., SureshKumar, H. K., Klement, L., Reisser, Y., Wernike, C., Nischang, V., Jordan, P. M., Werz, O., Hoffmann, C., Löffler, B., et al. (2025). High-fat diet impairs microbial metabolite production and aggravates influenza A infection. Cell Communication and Signaling. DOI: 10.1186/s12964-025-02367-w

  3. Hussain, I., Sureshkumar, H. K., Bauer, M., & Rubio, I. (2023). Starvation protects hepatocytes from inflammatory damage through paradoxical mTORC1 signaling. Cells, 12(12), 1668. DOI: 10.3390/cells12121668

  4. Suresh Kumar, H. K., Gopikrishna, T., Tapasya, K., Perumal, K., & Elavarashi, E. (2023). A computational genome analysis of strain Bacillus subtilis MIZ-8 isolated from Bekang reveals a distinct chromosome and plasmid conferring selective advantage. Journal of Microbiology, Biotechnology and Food Sciences, 13(2), e9141. DOI: 10.55251/jmbfs.9141

  5. Gopikrishna, T., Suresh Kumar, H. K., Perumal, K., & Elangovan, E. (2021). Impact of Bacillus in fermented soybean foods on human health. Annals of Microbiology, 71, 30. DOI: 10.1186/s13213-021-01641-9

Ms. Harini Keerthana SureshKumar’s research advances the safety and precision of cancer surgery while deepening scientific understanding of immune responses, microbial interactions, and cellular signaling. Her contributions support improved clinical outcomes, inform translational innovations, and strengthen global efforts in oncology, infectious disease biology, and patient-centered healthcare.

Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Xinli Shi | Tumor | Best Researcher Award

Published on by Oncology

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3